Table 1.
Selected phase-II studies of novel agents in chronic graft-versus-host disease (cGVHD).
| Study | Novel therapy | Sample size | Response |
|---|---|---|---|
| Lopez et al8 | MMF | 24 | 75% |
| Baudard et al9 | MMF | 15 | 69% |
| Busca et al10 | MMF | 15 | 60% |
| Krejci et al11 | MMF | 11 | 64% |
| Kim et al12 | MMF | 13 | 77% |
| Mookerjee et al13 | MMF | 26 | 46% |
| Ratanathorn et al14 | Rituximab | 8 | 50% |
| Canniga Van Dijk et al15 | Rituxumab | 6 | 83% |
| Cutler et al17 | Rituximab | 21 | 70% |
| Couriel et al18 | Sirolimus | 35 | 63% |
| Jurado et al19 | Sirolimus | 47 | 81% |
| Johnston et al20 | Sirolimus | 16 | 93% |
| Greinix et al22 | ECP | 15 | 80% (skin) |
| Apisarnthanarax et al23 | ECP | 32 | 56% (skin) |
| Foss et al24 | ECP | 25 | 80% (skin) |
| Kanold et al25 | ECP | 63 | 63% |
| Couriel et al21 | ECP | 71 | 61% |
| Akpek et al26 | Pulsed steroids | 61 | 75% |
| Jacobsohn et al27 | Pentostatin | 58 | 55% |
| Willenbacher et al28 | Daclizumab | 4 | 75% |
| Chiang et al29 | Etanercept | 10 | 70% |
| Browne et al31 | Thalidomide | 37 | 38% |
| Parker et al32 | Thalidomide | 80 | 20% |
MMF, mycophenolate mofetil; ECP. extracorporeal photopheresis.